BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tykerb: Additional Phase III data

Additional data from the double-blind, international Phase III LOGiC trial in 545 patients with locally advanced, unresectable or metastatic HER2-positive gastric cancer showed that lapatinib plus capecitabine and oxaliplatin chemotherapy led to a median OS, the primary endpoint, of 12.2 months vs. 10.5 months for placebo plus chemotherapy (p=0.3492). Lapatinib plus capecitabine and oxaliplatin chemotherapy...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >